#United States #New York #Semaglutide #Hoth Therapeutics #GDNF

Hoth Therapeutics Reports Positive Results in GDNF Study

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical firm focused on innovative therapies, recently disclosed promising findings from its HT-VA study. This research, developed in conjunction with the U.S. Department of Veterans Affairs and Emory University, indicates that Glial Cell-Derived Neurotrophic Factor (GDNF) plays a significant role in reshaping liver fat metabolism at the genetic level. The study presents encouraging evidence of GDNF's efficacy in addressing metabolic-associated fatty liver disease (MAFLD) and obesity

Significant Findings from the HT-VA Study

The HT-VA study unveiled that GDNF has a profound impact on liver metabolism. The results indicated notable changes in key genetic expressions linked to fat production and metabolism. Here are some highlights:

• - Reduction of Srebf1: The study demonstrated a statistically significant decrease in Srebf1, a gene that is essential for fat production in the liver. This reduction implies that GDNF effectively limits the generation of fat in the liver.
• - Activation of Pparα: Additionally, the study noted an increase in the expression of Pparα, which is vital for fat metabolism and burning. This activation allows for better management of fat within the body, thus enhancing metabolic efficiency.
• - Comparison with Semaglutide: When compared to Semaglutide, a widely used GLP-1 agonist for weight loss, GDNF showcased superior results in influencing gene expression related to liver fat regulation.

These findings position GDNF not merely as a weight-loss agent but as a potential therapy that modifies the underlying biological factors contributing to fat accumulation in the liver.

GDNF's Differentiated Approach

The implications of these results are substantial. Unlike existing treatments that primarily focus on aiding weight loss, GDNF tackles the heart of metabolic dysfunction by shutting down fat creation while promoting fat burning. This dual-action mechanism could pave the way for GDNF as a groundbreaking treatment for MAFLD and obesity, addressing the root causes rather than merely the symptoms.

Robb Knie, CEO of Hoth Therapeutics, remarked, "These results demonstrate that GDNF is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists."

Implications and Future Directions

The strategic implications of this research are significant, indicating a plausible entry into the MAFLD, NASH, and obesity markets. As Hoth Therapeutics seeks to differentiate itself from traditional GLP-1 therapies, the potential of GDNF as a first-in-class metabolic reprogramming treatment becomes clearer.

Moving forward, Hoth Therapeutics is committed to:

• - Advancing the HT-VA findings through additional preclinical validation studies.
• - Exploring clinical development pathways for metabolic and liver diseases.
• - Seeking strategic partnerships that could expedite the therapeutic development process.

Hoth Therapeutics stands as a catalyst in early-stage pharmaceutical research, striving to improve the quality of life for patients with innovative solutions. As the company continues to navigate the complexities of drug development, the results from the HT-VA study mark a pivotal moment in their journey toward revolutionizing the treatment landscape for metabolic disorders. For more on their progress and research initiatives, visit Hoth Therapeutics.